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A prevalence threshold to define rare diseases is needed for orphan drug designation. Here, we propose a bottom-up
approach to defining rare diseases for China, based on the minimum number of patients needed for the industry to
make a reasonable profit on a new drug. To obtain this patient population size, we considered three factors:
(1) the industry research and development cost per new drug; (2) the sales per new drug to recoup its research
and development costs and generate profit; (3) the highest affordable cost for one patient’s treatment in a given
healthcare system. Using this model, we estimate that, with the current level of innovation in the pharmaceutical
industry in China, between 300,000 and 500,000 patients could be a reference threshold to define rare diseases.
Compared with other proposals, this evidence-based definition is more useful for designing rare diseases and
orphan drug policies for China.
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A rare disease is generally one with low prevalence but
which is seriously debilitating or life-threatening. For
most rare diseases, there are currently no curative or
disease-modify treatments available. The definition for a
rare disease differs between legislation and policies, and
there is no single, widely accepted definition for rare
diseases worldwide. Typically, the existing definitions
include a criterion or cutoff of disease incidence or preva-
lence. For example, the United States (US) Food and Drug
Administration (FDA) considers a rare disease to be one
that affects <200,000 patients, and the criteria for the
European Union (EU) and Japan are <250,000 patients
(5 in 10,000) and <50,000 patients, respectively [1].Discussion
Public awareness of rare diseases has been increasing in
China in the past decade. However, China has no legisla-
tion for the development of treatment for rare diseases,
and gaps in the availability of orphan treatments for* Correspondence: jxhan9888@aliyun.com
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drug development in US and EU has evoked some
experts and patient advocacy groups to propose that
legislation for rare diseases and orphan drugs should
be a high priority for China. China does not have an
official definition of rare disease, and although the def-
inition of the World Health Organization (prevalence
between <0.65 – 1%) has been frequently used as a ref-
erence, this is not enough to provide a guide for the
Chinese government to develop specific strategies for
orphan drugs. For this, a prevalence threshold of rare
diseases specific to China is necessary. In China, most
of the rare diseases lack epidemiological data at the
population level. Although the prevalence of several
rare diseases has been extrapolated [2,3], actual patient
numbers or the true prevalence of most rare diseases
is often highly uncertain [4]. In 2010, some experts
suggested that rare disease be defined by a prevalence
of less than 1 in 500,000 or a neonatal morbidity of less
than 1 in 10,000 [5]. However, this definition lacked
supporting evidence.
Under normal marketing conditions, the pharmaceutical
industry lacks incentive to commit to the high costs asso-
ciated with developing a new drug for a disease with low. This is an Open Access article distributed under the terms of the Creative
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expected drug sales are inadequate to cover the return
on investment in a new drug, such development would
be financially unviable for the industry. In light of this,
a rare disease could be defined as one that is not cost
effective to treat [6]. Legislative incentives, for example,
tax credits, research aids, simplification of the marketing
authorization procedures, or extended market exclusivity
can be introduced to make developing orphan drugs
profitable.
Here, we suggest a simple approach to define rare
diseases for China based on the return on investment in
new orphan drugs. The core idea is to utilize the figure
for the highest costs provided for one disease by a
healthcare system to determine how many patients are
needed to make a reasonable profit for developing a new
drug. To obtain this patient population size in China,
the following should be considered: (1) the research and
development costs per new drug; (2) the sales of new
drug needed to recoup its research and development
costs and generate profit; (3) the highest amount payable
to one patient in a given healthcare system.
Innovative drug research and development in China
has progressed rapidly in the past decade. Although
research and development costs are relatively low, the
Chinese pharmaceutical industry lacks sufficient experi-
ence for innovative drug research and development and
has a significantly high failure rate. The current total
annual research and development spending in the life
science-related industry as a whole on innovative drugs
is about $5.0 billion [7], and an average of four innova-
tive drugs have been approved for marketing per year in
the past decade [8]. These innovative drugs only include
chemical and biological drugs in class 1 (that is, not
those included in traditional Chinese medicine and
vaccines), which are defined by the Chinese State Food
and Drug Administration (SFDA) as not being previously
approved for marketing as a drug anywhere else in the
world. Therefore, we estimate the research and develop-
ment cost to develop a class 1 drug (including the costs of
failures) in China to be about $1.2 billion. To recoup $1.2
billion in research and development costs and generate
reasonable profit, sales per new drug should reach
about $15–24 billion (based on research and development
as 5–8% of annual sales in China [7]). Currently, the med-
ical reimbursement ceiling in China is $50,000 annually
per person, which means that at least 300,000–500,000
patients are needed per drug to guarantee the return
on investment and ensure profit incentives for further
research and investor support. Therefore, under the
current level of innovation in the Chinese pharmaceutical
industry, we suggest between 300,000–500,000 patients
(about 2–4 out of 10,000, based on the Chinese popula-
tion of 1.35 billion) as a reference threshold to define rarediseases. This prevalence threshold is greater than the
threshold levels in the US and EU, but is comparative
when the national population is considered. To our
knowledge, this is the first evidence-based proposal for
the definition of rare diseases.
China has a specific pharmaceutical market which is
research and development focused (unique among devel-
oping countries), enabling the development of innovative
orphan drugs. Additionally, and in contrast to practice
in the US and EU, Chinese domestic research and devel-
opment companies connect directly to the local market,
not to the worldwide market. Most of the new drugs
developed in China are used only or predominantly
domestically, allowing global incentives and returns to
be ignored in our model. Thus, our model determining
the prevalence cutoff for rare diseases is only suitable for
China, and could not be applied in an international,
cross-border setting.
The limitations of this model are: (1) it was assumed that
all patients would be diagnosed, treated and reimbursed by
healthcare systems; (2) delays on return of investment are
not considered. If these uncertain economic and environ-
mental factors are included, the prevalence threshold
might be higher than proposed. However, at least
300,000–500,000 could be a reference for the lower
limit of prevalence to define rare diseases for China.
Currently, innovative drugs developed solely by domes-
tic Chinese pharmaceutical companies are now all focused
on common diseases. Without incentives, it is unlikely
that domestic Chinese pharmaceutical companies will
cover the costs of bringing an orphan drug to market. The
Chinese government has not established a special program
or funding plan for orphan drug research and develop-
ment, but China is reforming its national health insurance
and health care systems.
Finally, the prevalence threshold for the definition of
rare diseases should be relatively fixed, though flexible,
so that when the determining factors (costs of drug
development, sales of new drugs and affordability of
national healthcare systems) change dramatically, the
definition could be re-evaluated. Moreover, the threshold
suggested here is only a starting point, the final defin-
ition will depend on more detailed data on investment
returns for new drugs in China.
Summary
Based on this analysis, we propose that in future policies
or legislation for rare diseases, orphan drugs treating
seriously debilitating or life-threatening diseases with a
prevalence between 300,000–500,000 should be a high
priority in China.
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